Alps Advisors Inc. bought a new position in Incyte Co. (NASDAQ:INCY) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,746 shares of the biopharmaceutical company’s stock, valued at approximately $408,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Eagle Asset Management Inc. purchased a new stake in Incyte in the first quarter worth $37,747,000. Signature Estate & Investment Advisors LLC purchased a new stake in Incyte in the first quarter worth $1,152,000. Emerald Advisers LLC increased its position in Incyte by 23.1% in the first quarter. Emerald Advisers LLC now owns 14,852 shares of the biopharmaceutical company’s stock worth $1,277,000 after buying an additional 2,790 shares during the last quarter. Public Employees Retirement Association of Colorado increased its position in Incyte by 5.4% in the first quarter. Public Employees Retirement Association of Colorado now owns 34,265 shares of the biopharmaceutical company’s stock worth $2,947,000 after buying an additional 1,763 shares during the last quarter. Finally, Shikiar Asset Management Inc. increased its position in Incyte by 46.3% in the first quarter. Shikiar Asset Management Inc. now owns 33,500 shares of the biopharmaceutical company’s stock worth $2,881,000 after buying an additional 10,600 shares during the last quarter. 92.20% of the stock is owned by institutional investors and hedge funds.

INCY has been the subject of a number of recent research reports. Royal Bank of Canada downgraded Incyte from an “outperform” rating to a “sector perform” rating and set a $89.00 target price for the company. in a research report on Wednesday, April 3rd. They noted that the move was a valuation call. Argus raised their target price on Incyte from $83.00 to $98.00 and gave the stock a “buy” rating in a research report on Monday, February 25th. Barclays downgraded Incyte from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $90.00 to $82.00 in a research report on Friday, May 3rd. Zacks Investment Research lowered Incyte from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 23rd. Finally, UBS Group lowered Incyte from a “buy” rating to a “neutral” rating and raised their price target for the stock from $75.00 to $82.00 in a report on Wednesday, January 16th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Incyte presently has a consensus rating of “Hold” and an average price target of $92.07.

In other news, EVP Paula J. Swain sold 10,000 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $87.01, for a total value of $870,100.00. Following the completion of the transaction, the executive vice president now directly owns 38,295 shares of the company’s stock, valued at $3,332,047.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 17.10% of the stock is owned by company insiders.

Incyte stock opened at $75.99 on Thursday. Incyte Co. has a one year low of $57.00 and a one year high of $88.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.22 and a quick ratio of 5.21. The firm has a market capitalization of $16.24 billion, a PE ratio of 92.67 and a beta of 1.31.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.29. Incyte had a return on equity of 13.28% and a net margin of 12.66%. The firm had revenue of $497.86 million during the quarter, compared to analyst estimates of $488.00 million. During the same period last year, the company earned ($0.01) earnings per share. The business’s revenue for the quarter was up 30.2% on a year-over-year basis. Analysts anticipate that Incyte Co. will post 1.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “4,746 Shares in Incyte Co. (INCY) Purchased by Alps Advisors Inc.” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://theolympiareport.com/2019/05/16/4746-shares-in-incyte-co-incy-purchased-by-alps-advisors-inc.html.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Read More: Stock Symbol

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.